Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review

Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article describes the practical clinical issues associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobo, Manuel, Rodríguez-Abreu, Delvys, Pérez Parente, Diego, Ruiz Gracia, Pedro, González, Jorge G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140026/
https://www.ncbi.nlm.nih.gov/pubmed/33582978
http://dx.doi.org/10.1007/s40487-021-00139-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140026/
https://www.ncbi.nlm.nih.gov/pubmed/33582978
http://dx.doi.org/10.1007/s40487-021-00139-3

Ejemplares similares